Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient

Dario Cattaneo, Paola Meraviglia, Valeria Cozzi, Sara Baldelli, Greta Milani, Emilio Clementi

Research output: Contribution to journalArticle

Abstract

An HIV-infected patient with very low atazanavir (ATV) plasma trough concentrations despite clinical signs of poor drug tolerability was described. By therapeutic drug monitoring (TDM), the authors found that the patient had an atypical ATV pharmacokinetics characterized by rapid drug absorption followed by very fast drug clearance probably attributable to his genetic background. This case underlines the importance of traditional and pharmacogenetic-based TDM for the individualization of ATV therapy in HIV-1 patients.

Original languageEnglish
Pages (from-to)204-206
Number of pages3
JournalFundamental and Clinical Pharmacology
Volume26
Issue number2
DOIs
Publication statusPublished - Apr 2012

    Fingerprint

Keywords

  • HAART
  • HIV
  • Pharmacogenetics
  • Pharmacokinetics
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Cattaneo, D., Meraviglia, P., Cozzi, V., Baldelli, S., Milani, G., & Clementi, E. (2012). Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient. Fundamental and Clinical Pharmacology, 26(2), 204-206. https://doi.org/10.1111/j.1472-8206.2010.00905.x